Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Rating of “Moderate Buy” by Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has earned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $48.1250.

AVTX has been the topic of several analyst reports. Wedbush decreased their price objective on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Guggenheim initiated coverage on Avalo Therapeutics in a report on Monday, February 2nd. They set a “buy” rating and a $50.00 price target on the stock. Citizens Jmp reduced their price target on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Finally, BTIG Research boosted their price target on Avalo Therapeutics from $40.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, May 6th.

Avalo Therapeutics Trading Down 1.1%

AVTX opened at $15.95 on Friday. The company has a market cap of $838.43 million, a P/E ratio of -2.92 and a beta of 0.78. The business’s 50-day moving average price is $15.77 and its 200-day moving average price is $16.40. Avalo Therapeutics has a 12 month low of $3.58 and a 12 month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. Equities research analysts forecast that Avalo Therapeutics will post -2.72 earnings per share for the current fiscal year.

Insider Activity at Avalo Therapeutics

In related news, insider Paul Varki sold 75,063 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the transaction, the insider owned 3,634 shares in the company, valued at $73,297.78. The trade was a 95.38% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $16.15, for a total value of $411,695.80. Following the transaction, the insider owned 3,622 shares in the company, valued at approximately $58,495.30. This represents a 87.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 138,078 shares of company stock worth $2,501,346 in the last 90 days. Company insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC increased its holdings in Avalo Therapeutics by 39.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after purchasing an additional 382,300 shares during the period. Affinity Asset Advisors LLC grew its holdings in shares of Avalo Therapeutics by 27.6% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after acquiring an additional 289,786 shares during the period. Nantahala Capital Management LLC raised its position in shares of Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after acquiring an additional 240,000 shares in the last quarter. Caligan Partners LP raised its position in shares of Avalo Therapeutics by 5.8% in the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock worth $16,009,000 after acquiring an additional 48,200 shares in the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Avalo Therapeutics in the 3rd quarter valued at approximately $10,390,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.